The global antifungal agents market is anticipated to grow at a considerable CAGR of nearly 3.5% during the forecast period (2021-2027). The factor contributing to the growth of antifungal agents include the rise in the number of COVID-19 cases and diabetic patients. Moreover, due to COVID-19, there is an increase in the number of viral infections and bacteria’s which is causing fungal infections, and patients are at high risk of healthcare-associated infections including candidemia or bloodstream infections caused by Candida. Diabetic patients are at more risk of getting affected by black fungus infection which is also known as Mucormycosis.
Browse the full report description Global Antifungal Agents Market Size, Share & Trends Analysis Report, By Drug Class (Polyene, Echinocandins, Allylamines, and Azole), By Dosage Type (Powder, Ointment, and Drugs), By Route of Administration (Parenteral, Topical, and Oral), Forecast Period 2021-2027 at https://www.omrglobal.com/industry-reports/antifungal-agents-market
In addition, the companies are strategically increasing their product portfolios to grow in the market. For instance, in April 2021, Pfizer acquired Amplyx Pharmaceuticals, Inc. which is a privately-held company working in the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Fosmnaogepix (APX001) is Amplyx lead compound and is a novel asset that is under development for the treatment of invasive fungal infections. Accordingly, infectious disease is responsible for more than 8.4 million mortalities annually, globally.
Furthermore, In January 2019, Mayne Pharma Group Ltd. launched TOLSURA (SUBa - itraconazole) 65 mg capsule in the US. TOLSURA is a formulation of itraconazole for the treatment of fungal infection including blastomycosis, histoplasmosis, and aspergillosis. These infections commonly occur in immunocompromised patients such as patients with a history of cancer, transplants, and HIV/AIDS. The company received approval for TOLSURA in 2018, from the US Food and Drug Administration (FDA). Additionally, in November 2019, SCYNEXIS, Inc. developed Ibrexafungerp for the treatment of Candida Auris and other difficult-to-treat fungal infections. Thus, the mergers & acquisitions, partnerships and collaborations and new and innovative product development in the antifungal agents are driving the growth of the market during the forecast period.
Market Coverage
o By Drug Class
o By Dosage Type
o By Route of Administration
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Antifungal agents Market Report Segment
By Drug Class
By Drug Dosage
By Route of Administration
Global Antifungal agents Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy
@ https://www.omrglobal.com/request-sample/antifungal-agents-market